# Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients

> **NCT01439789** · PHASE3 · TERMINATED · sponsor: **Zensun Sci. & Tech. Co., Ltd.** · enrollment: 146 (actual)

## Conditions studied

- Chronic Heart Failure

## Interventions

- **DRUG:** rhNRG-1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01439789
- **Lead sponsor:** Zensun Sci. & Tech. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 146 (ACTUAL)
- **Why stopped:** Sponsor has designed another study with different endpoint to replace the current study
- **Last updated:** 2017-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01439789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01439789, "Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01439789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*